SG10201811109PA - Methods of treating ttp with immunoglobulin single variable domains and uses thereof - Google Patents
Methods of treating ttp with immunoglobulin single variable domains and uses thereofInfo
- Publication number
- SG10201811109PA SG10201811109PA SG10201811109PA SG10201811109PA SG10201811109PA SG 10201811109P A SG10201811109P A SG 10201811109PA SG 10201811109P A SG10201811109P A SG 10201811109PA SG 10201811109P A SG10201811109P A SG 10201811109PA SG 10201811109P A SG10201811109P A SG 10201811109PA
- Authority
- SG
- Singapore
- Prior art keywords
- single variable
- treating
- variable domains
- immunoglobulin single
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Methods of treating TIP with immunoglobulin single variable domains and uses thereof The present invention is based on the f in ding that administration of polypeptides comprising at least one Immuno globulin single variable domains against vW F to human TTP patients provides a significant decrease in the time to response. The in vention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Wi llebrand Factor (v WF) for u se in treating a vW F - related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP. No figure is to accompany the abstract.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2013007A NL2013007B1 (en) | 2014-06-16 | 2014-06-16 | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| US201462030817P | 2014-07-30 | 2014-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811109PA true SG10201811109PA (en) | 2019-01-30 |
Family
ID=51541255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811109PA SG10201811109PA (en) | 2014-06-16 | 2015-06-16 | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |
| SG11201610488QA SG11201610488QA (en) | 2014-06-16 | 2015-06-16 | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610488QA SG11201610488QA (en) | 2014-06-16 | 2015-06-16 | Methods of treating ttp with immunoglobulin single variable domains and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10858445B2 (en) |
| EP (6) | EP4059513A1 (en) |
| JP (3) | JP6688746B2 (en) |
| KR (2) | KR102568585B1 (en) |
| CN (1) | CN106559985A (en) |
| AU (2) | AU2015276237B2 (en) |
| CA (1) | CA2952103A1 (en) |
| ES (5) | ES2915473T3 (en) |
| HK (3) | HK1256731A1 (en) |
| IL (1) | IL249540B (en) |
| NL (1) | NL2013007B1 (en) |
| PL (5) | PL3332800T3 (en) |
| PT (5) | PT3332800T (en) |
| RU (1) | RU2704444C2 (en) |
| SG (2) | SG10201811109PA (en) |
| WO (1) | WO2015193326A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CN107340225B (en) * | 2017-07-13 | 2019-07-05 | 徐州医科大学 | One kind being based on Flow cytometry platelet receptor GPIba extracellular fragment digestion method |
| WO2019154867A1 (en) * | 2018-02-06 | 2019-08-15 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
| AU2022345251A1 (en) | 2021-09-17 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| WO2023108095A1 (en) * | 2021-12-10 | 2023-06-15 | Emory University | Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
| AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| EP1621554B2 (en) | 1992-08-21 | 2012-08-29 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
| EP1198572A2 (en) | 1999-08-02 | 2002-04-24 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2004015425A1 (en) | 2002-08-07 | 2004-02-19 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
| EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| ES2542330T3 (en) | 2003-01-10 | 2015-08-04 | Ablynx N.V. | Therapeutic polypeptides, homologs thereof, fragments thereof and their use in modulating platelet-mediated aggregation |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| WO2005018629A1 (en) | 2003-08-12 | 2005-03-03 | Yarbrough William M | Treatment for acne vulgaris and method of use |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| PT1836500E (en) | 2005-01-14 | 2010-09-28 | Ablynx Nv | Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets |
| CA2960105A1 (en) * | 2005-05-20 | 2006-11-23 | Ablynx Nv | Single domain vhh antibodies against von willebrand factor |
| JP2010500876A (en) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling |
| JP2010518839A (en) | 2007-02-21 | 2010-06-03 | アブリンクス エン．ヴェー． | Amino acid sequence directed against vascular endothelial growth factor and polypeptides comprising it for treating conditions and diseases characterized by excessive and / or pathological angiogenesis or angiogenesis |
| CN101796072B (en) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against RANK-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| US20110158996A1 (en) | 2008-03-21 | 2011-06-30 | Ablynx N.V. | Von willebrand factor specific binders and methods of use therefor |
| CN104740631B (en) | 2008-10-29 | 2019-04-16 | 阿布林克斯公司 | The preparation of single domain antigen-binding molecule |
| US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
| EP2506874A1 (en) | 2009-12-01 | 2012-10-10 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| DE20187001T1 (en) * | 2010-11-05 | 2021-04-01 | Novartis Ag | METHOD OF TREATMENT OF PSORIASUS ARTHRITIS WITH IL-17 ANTAGONISTS |
| WO2012171031A1 (en) | 2011-06-10 | 2012-12-13 | Baxter International Inc. | Treatment of coagulation disease by administration of recombinant vwf |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
-
2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
-
2015
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en active Pending
- 2015-06-16 PT PT181536764T patent/PT3332800T/en unknown
- 2015-06-16 PL PL18153676T patent/PL3332800T3/en unknown
- 2015-06-16 PT PT181536749T patent/PT3335724T/en unknown
- 2015-06-16 ES ES18153673T patent/ES2915473T3/en active Active
- 2015-06-16 PL PL15729829T patent/PL3154569T3/en unknown
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/en unknown
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/en active IP Right Grant
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/en active Active
- 2015-06-16 ES ES18153676T patent/ES2831865T3/en active Active
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/en unknown
- 2015-06-16 PT PT181536731T patent/PT3335723T/en unknown
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 PL PL18153671T patent/PL3366305T3/en unknown
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 ES ES15729829T patent/ES2881331T3/en active Active
- 2015-06-16 PT PT157298290T patent/PT3154569T/en unknown
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en active Application Filing
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/en active IP Right Grant
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/en active Pending
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/en active
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/en active Active
- 2015-06-16 ES ES18153671T patent/ES2843642T3/en active Active
- 2015-06-16 PT PT181536715T patent/PT3366305T/en unknown
-
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
-
2018
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
- 2018-01-26 US US15/880,978 patent/US20180155441A1/en active Pending
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-12-10 HK HK18115789.3A patent/HK1256731A1/en unknown
- 2018-12-10 HK HK18115787.5A patent/HK1256730A1/en unknown
-
2019
- 2019-01-17 HK HK19100857.1A patent/HK1258508A1/en unknown
-
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/en active Active
-
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
-
2022
- 2022-07-11 JP JP2022110921A patent/JP2022160431A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811109PA (en) | Methods of treating ttp with immunoglobulin single variable domains and uses thereof | |
| MX2022004072A (en) | Factor xi antibodies and methods of use. | |
| MX2019005594A (en) | Agents, uses and methods for the treatment of synucleinopathy. | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| UA118453C2 (en) | Modulation of tumor immunity | |
| MX2018014175A (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE. | |
| MX2016010951A (en) | Multimeric fc proteins. | |
| MX2019011117A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof. | |
| MX2018013762A (en) | Cd40l-fc fusion polypeptides and methods of use thereof. | |
| PH12019502763A1 (en) | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof | |
| MX2019010994A (en) | Methods for treating complement-mediated diseases and disorders. | |
| SG10201809701TA (en) | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent | |
| MX2019011624A (en) | Methods and compositions for reduction of immunogenicity. | |
| MX2019010397A (en) | Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide. | |
| MX2017000378A (en) | Improved aã protofibril binding antibodies. | |
| MX2017009047A (en) | Dosage regimen for madcam antagonists. | |
| MX2019001958A (en) | Methods of treating crohn's disease with an anti-nkg2d antibody. | |
| EA201591055A1 (en) | POLYPEPTIDE OF SOLUBLE RECEPTOR 3 FIBROBAL GROWTH FACTOR (FGR3) FOR APPLICATION FOR THE PURPOSE OF PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH DECOMPOSITION OF SKELETON GROWTH | |
| MY176219A (en) | Combination therapy for cancer | |
| NZ730664A (en) | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | |
| MX2018009499A (en) | Egfl6 specific monoclonal antibodies and methods of their use. | |
| MX2020002750A (en) | Il-6r antibody and antigen binding fragment thereof and medical use. | |
| BR112017004590A2 (en) | Methods for treating autoimmune disease with the use of a cd40l-targeted domain antibody | |
| MX2017003015A (en) | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof. | |
| MX2019014090A (en) | Methods for the treatment of chronic pouchitis. |